Everest Medicines reported its novel TROP-2 antibody-drug conjugate met its primary endpoint in a China Phase II trial in metastatic triple-negative breast cancer (TNBC) patients. In 2019, Everest in-licensed the candidate in an $835 million agreement. Sacituzumab govitecan, which is marketed as Trodelvy® in the US by Gilead , met its primary endpoint of overall response rate as a third line treatment for TNBC. Earlier this year, Everest began a China Phase III trial of the ADC in patients with metastatic urothelial cancer. More details.... Stock Symbols: (HK 1952) (NSDQ: GILD) Share this with colleagues: // //